Roomasa Channa, MD has been selected to participate in the Association for Research in Vision and Ophthalmology (ARVO) Women’s Leadership Development Program, starting in 2022. This highly-competitive program began in 2016 and is open to early- …
Amy Pikalek
DOVS and UW School of Veterinary Medicine Team Up for Ocular Pathology Day
The UW Department of Ophthalmology and Visual Sciences (DOVS) and the UW School of Veterinary Medicine were proud to have successfully hosted another annual Ocular Pathology Day on September 17, 2021. The morning began virtually …
Mary Pratt, MD, Honored as Distinguished Alumni in 2020
Mary Van Horn Pratt, MD’61 (Residency ’65, Retina Fellowship ’66) was selected as the UW Ophthalmology Alumni Association’s Distinguished Alumni in October 2020. Mary was the driving force behind the campaign to update the James …
AAO Recognizes Dr. Terri Young as ‘Guest of Honor’ at 2021 Conference
Dr. Terri Young – Chair of the Department of Ophthalmology and Visual Sciences at UW-Madison – was recognized as an official ‘Guest of Honor’ at this year’s American Academy of Ophthalmology (AAO) annual conference. She …
CLN-0500
A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of Dextenza for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
UNITY
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
PEP
Patient Experience and Preference (PEP) Study in nAMD and DME
Teaming Up for Gene Therapy
*This article originally appeared in the McPherson Eye Research Institute Summer 2021 InSights Newsletter Millions of Americans currently battle inherited visual disorders, armed with very few therapeutic options. Recent advances in genome editing, which many believe …